Symbiosis Pharmaceutical Services
Stirling, United Kingdom
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
76.8
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (8)
✓ HC GMP (3)
Quick Facts: Symbiosis Pharmaceutical Services
- Signal Score
- 76.8/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Clean MHRA record: 8 compliant GMP certificates (no deductions)
- Headquarters
- Stirling, United Kingdom
- Modalities
- Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Symbiosis Pharmaceutical Services
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Clean MHRA record: 8 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, MHRA GMDP
Clean MHRA record: 8 compliant GMP certificates (no deductions)
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-01-31)
MHRA GMP Certificates8 on record
Most Recent HC OutcomeCompliant · 2025-02-04
HC Attribution3 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean MHRA record: 8 compliant GMP certificates (no deductions)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Stirling, UK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Symbiosis Pharmaceutical Services FDA Inspection History
2025-01
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-01-31 |
Symbiosis Pharmaceutical Services Limited
Stirling
Facility-linked
|
Human Cellular, Tissue, and Gene Therapies | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Symbiosis Pharmaceutical Services MHRA GMP Compliance 8 certificates
2025-02
2025-02
2025-02
2025-02
2024-08
2024-08
2023-09
2023-09
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 40211 Insp IMP 40211/405290-0019[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/37423042-0004[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/405290-0020[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/37423042-0005[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/33209260-0005[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/33209260-0006[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [V] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
cell and gene therapy (CGT) · 1 site
- Stirling, United Kingdom · Symbiosis Pharmaceutical Services Limited — cell and gene therapy (CGT) · valid to Nov 7, 2028
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Frequently Asked Questions About Symbiosis Pharmaceutical Services
How many FDA inspections does Symbiosis Pharmaceutical Services have on record?
CDMO Signal tracks 1 FDA inspection for Symbiosis Pharmaceutical Services, sourced from the FDA inspection database. See the full inspection history above.
Has Symbiosis Pharmaceutical Services received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Symbiosis Pharmaceutical Services.
Does Symbiosis Pharmaceutical Services hold EMA or MHRA GMP certificates?
CDMO Signal tracks 8 MHRA GMP certificates for Symbiosis Pharmaceutical Services.
What is Symbiosis Pharmaceutical Services's CDMO Signal Score?
Symbiosis Pharmaceutical Services has a Signal Score of 77/100, based on quality, operations, financial stability, and capacity data.
Evaluating Symbiosis Pharmaceutical Services for a manufacturing program?
Use the free AI matchmaker to compare Symbiosis Pharmaceutical Services against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
eXmoor Pharma
Bristol, United Kingdom
Signal Score: 78.1
Cell Therapy, AAV
HiTech Health
London, United Kingdom
Signal Score: 76.8
Cell Therapy
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Ori Biotech
London, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy, AAV
Compare Symbiosis Pharmaceutical Services with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.